Key Takeaways:
NEW YORK – A securities class action lawsuit has been initiated against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plummeted over 37 percent, according to a press release from law firm Levi & Korsinsky on April 6, 2026.
The lawsuit, announced by Levi & Korsinsky, invites institutional investors who incurred losses on AQST stock to consider lead plaintiff opportunities. The legal action pertains to investments made during the class period from June 16, 2025, through January 8, 2026.
The core of the class action revolves around the significant drop in Aquestive's stock value, which the lawsuit alleges has caused substantial losses for investors. The firm is seeking to recover damages for Aquestive investors under the federal securities laws.
For investors, this lawsuit introduces a period of uncertainty and potential for further stock volatility. The legal proceedings could result in significant financial penalties for Aquestive and may impact the company's ability to raise capital in the near future.
The sharp decline in stock value and the subsequent lawsuit places Aquestive Therapeutics in a precarious position. Investors will be closely watching for the company's official response and any further developments in the class action suit.
This article is for informational purposes only and does not constitute investment advice.
